 I. To estimate the maximum tolerated dose MTD andor recommended phase 2 dose RP2D of pevonedistat administered as an intravenous infusion on days 1, 8, 10, and 12 of a 28-day cycle cycle 1, and on days 1, 3, and 5 of a 21-day cycle cycle 2 and beyond in combination with irinotecan hydrochloride irinotecan administered as an intravenous infusion on days 8-12 of cycle 1 and days 1-5 of cycles 2 and temozolomide administered orally on day 1 alone and on days 8, 10 and 12 in cycle 1 and days 1-5 of cycles 2 in children with recurrent or refractory solid tumors, including central nervous system CNS tumors and lymphoma. 